REGNRegeneron Pharmaceuticals
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Oversold (RSI 30). Price is +1% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Lightly shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 1.0% since the previous count, down from 3.1% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How REGN is trading
Regeneron Pharmaceuticals is +25% over the past year while the S&P 500 is +18%: 6.9 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +1.0%
vs 200-day average · close to trend
- RSI (14)
- 30
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 12%
Below its 52-week high
Details›
- Last close2026-10-09
- $746.46
- 1 monthS&P 500 +2.7%
- −5.9%
- 1 yearS&P 500 +18%
- +25%
- 5 yearsS&P 500 +88%
- +18%
- vs 50-day average$785.55
- −5.0%
- 52-week high
- $852.16
- 52-week low
- $553.32
- Annualised volatility
- 37%
| Year | Return |
|---|---|
| 2026 (year to date) | −3.0% |
| 2025 | +9.0% |
| 2024 | −19% |
| 2023 | +22% |
| 2022 | +14% |
| 2021 | +31% |
| 2020 | +29% |
| 2019 | +0.53% |
| 2018 | −0.65% |
| 2017 | +2.4% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +0.40% |
| Feb | 10 | 8 of 10 | +2.7% |
| Mar | 10 | 6 of 10 | +3.2% |
| Apr | 10 | 3 of 10 | −4.8% |
| May | 10 | 5 of 10 | −0.24% |
| Jun | 10 | 8 of 10 | +4.1% |
| Jul | 11 | 9 of 11 | +4.5% |
| Aug | 11 | 7 of 11 | +5.2% |
| Sep | 11 | 2 of 11 | −3.1% |
| Oct | 11 | 4 of 11 | −2.7% |
| Nov | 10 | 6 of 10 | +3.8% |
| Dec | 10 | 4 of 10 | −0.61% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry